Preferred Label : Trametinib;
NCIt synonyms : MEK Inhibitor GSK1120212; N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide;
NCIt definition : An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K;
MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration,
trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition
of growth factor-mediated cell signaling and cellular proliferation in various cancers.
MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated
in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK
signaling pathway that regulates cell growth.;
UNII : 33E86K87QN;
InChIKey : LIRYPHYGHXZJBZ-UHFFFAOYSA-N;
CAS number : 871700-17-3;
Molecule name : GSK 1120212; JTP-74057; GSK-1120212; GSK 212; GSK-212; JTP 74057;
Chemical formula : C26H23FIN5O4;
Codes from synonyms : 508;
Origin ID : C77908;
UMLS CUI : C2697961;
Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- Currated CISMeF NLP mapping
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
- is_component_of_chemotherapy_regimen
